Bill > S1269

This bill, the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2023, aims to reduce the price of insulin and provide patient protections with respect to the cost of insulin. The key provisions of the bill include: 1. Requiring group health plans and health insurance issuers to provide coverage of selected insulin products and limit cost-sharing to no more than $35 per 30-day supply, or 25% of the negotiated price net of concessions, whichever is lower. 2. Ensuring that cost-sharing for selected insulin products applies towards deductibles and out-of-pocket maximums. 3. Prohibiting plans from imposing prior authorization or other medical management requirements on selected insulin products, except for clinically justified safety reasons. 4. Requiring pharmacy benefit managers, third-party administrators, and health insurance issuers to remit 100% of rebates and other remuneration related to insulin utilization to the group health plan. 5. Expediting the development and review of competitive biosimilar insulin products to increase market competition and affordability. 6. Requiring a report on the extent of delays in getting insulin products to market, the impact of biosimilar competition, and recommended policy solutions. The bill aims to improve access to affordable insulin by placing limits on patient cost-sharing, increasing transparency around rebates and remuneration, and facilitating faster market entry of generic and biosimilar insulin products.

Health and Social Services

https://www.congress.gov/bill/118th-congress/senate-bill/1269/all-info